| Literature DB >> 32612380 |
Jeongsoo Kim1, SuHwan Shin2,3, YoungHyun Jeong4, So Yoon Kim5,6, Ho-Jin Lee4,7.
Abstract
PURPOSE: Although the use of opioids is increasing in South Korea, there have been no studies on the serious complications caused by the opioids. The aim of this study was to investigate the rare but serious complications through medicolegal analysis.Entities:
Keywords: acute pain; adverse drug events; complications; legislation and jurisprudence; medical liability; opioids
Year: 2020 PMID: 32612380 PMCID: PMC7323961 DOI: 10.2147/JPR.S256759
Source DB: PubMed Journal: J Pain Res ISSN: 1178-7090 Impact factor: 3.133
Figure 1Flowchart of the study.
General Characteristics of the Cases
| Characteristics | Total (n = 31) |
|---|---|
| Year of judgment | |
| <2010 | 11 (35.5) |
| ≥2010 | 20 (64.5) |
| Sex | |
| M/F | 9 (29)/13 (41.9) |
| Not described | 9 (29) |
| Age at the time of the procedure (years) | |
| <40 | 8a (25.8) |
| 40–59 | 6 (19.4) |
| ≥60 | 5 (16.1) |
| Not described | 12 (38.7) |
| Cause of opioid administration | |
| Acute pain | 28 (90.3) |
| Abdominal pain | 9 (29) |
| Postoperative pain | 8 (25.8) |
| Diagnostic test | 3 (9.7) |
| Headache | 2 (6.4) |
| Traumatic pain | 3 (9.7) |
| Labor pain | 2 (6.5) |
| Septic arthritis | 1 (3.2) |
| Chronic painb | 3 (9.7) |
| History of opioid use before event | 10 (32.2) |
| Underlying diseases | |
| Liver diseases | 5 (16.1) |
| Kidney diseases | 3 (9.6) |
| Cerebrovascular diseases | 2 (6.4) |
| Not described | 5 (16.1) |
Notes: Values are presented as median (interquartile range) or number (%). aThis included two fetuses and one 6-month-old infant. bThis included low back (n = 2) and calf pain (n = 1).
Detailed Information of Opioid Administration and Opioid-Induced Complications
| Characteristics | Total (n = 31) |
|---|---|
| Opioids type | |
| Pethidine | 13 (41.9) |
| Fentanyl/Morphine | 3 (9.7)/2 (6.5) |
| Pentazocine/Morphine/Sufentanil/Nalbuphine | 1 (3.2)/1 (3.2)/1 (3.2)/1 (3.2) |
| Combineda | 9 (29) |
| Concomitant use of non-opioid sedative medications | 4 (12.9) |
| Number of opioid administration | |
| Single dose | 14 (45.1) |
| 2 times | 4 (12.9) |
| ≥3 times | 7 (22.5) |
| Continuous infusionb | 6 (19.3) |
| Adverse event or outcome contended by plaintiffs of the total cases/Cases recognized by the court as opioid-related malpracticec | |
| Respiratory depression | 17 (54.8)/8c (25.8) |
| Delayed diagnosis | 2 (6.5)/2 (6.5) |
| Decreased consciousness | 3 (9.6)/0 |
| Opioids use disorder | 3 (9.6)/1 (3.2) |
| Fetal hypoxia | 2 (6.5)/1 (3.2) |
| Anaphylactic shock | 1 (3.2)/1 (3.2) |
| Hypotension | 1 (3.2)/0 |
| Gastrointestinal dysfunction | 1 (3.2)/0 |
| Cardiac arrest | 1 (3.2)/0 |
| Onset of symptoms | |
| In medical institution | 28 (90.3) |
| After discharge | 3 (9.6) |
| Severity of complications | |
| High (NAIC score 6–9) | 29d (93.5) |
| Medium (NAIC score 3–5) | 2 (6.5) |
| Low (NAIC score 0–2) | 0 (0) |
Notes: Values are presented as median (interquartile range) or number (%). aThis included one case with tramadol and transdermal fentanyl patch, one case with pethidine, tramadol, transdermal fentanyl patch, and patient-controlled analgesia using fentanyl, one case with pethidine, oxycontin, tramadol, and patient-controlled analgesia (unknown opioid), one case with pentazocine, pethidine, morphine and one case with tramadol, pethidine. bThis included patient-controlled analgesia (2 cases), transdermal fentanyl patch (2 cases), remifentanil infusion via infusion pump (1case) and sufentanil infusion via infusion pump (1 case). cThis included one criminal proceeding. dThis included a total of eighteen deaths.
Abbreviation: NAIC, National Association of Insurance Commissioners.
Judicial Characteristics from 31 Cases Related to Opioid Administration
| Characteristics | n = 31 |
|---|---|
| 1 (3.2) | |
| Neglect of observation | 1 (3.2) |
| 30 (96.8) | |
| Dismissal of opioid-related malpractice | 18 (58.1) |
| Violation of the duty of care related to opioid prescription | |
| Claims of plaintiffs | 30 (96.8) |
| Recognition of the court | 12 (38.7) |
| Neglect of observation | 10 (32.3) |
| Inappropriate drug choice | 4 (12.9) |
| Overdose | 3 (9.7) |
| Violation of the duty of explanation related to opioid prescription | |
| Claims of plaintiffs | 11 (36.7) |
| Recognition of the court | 2 (6.7) |
| Amount for damage – median USDa | |
| Claims of plaintiffsb | 169,053 (98,418–627,662) |
| Recognition of the courtc | 126,346 (77,275–379,219) |
Notes: Values are presented as median (interquartile range) or number (%). aThe exchange rate was converted to 1 United States Dollar =1165 Korean Won considering the mean exchange rate for 2019. bThe amount was not described in one opioid case. cThis included only events that opioid-related malpractice had not been dismissed.